EP1551964A4 - VERFAHREN UND ZUSAMMENSETZUNGEN ZUR VERLûNGERUNG DER LEBENSDAUER UND ERH HUNG DER STRESSRESISTENZ VON ZELLEN UND ORGANISMEN - Google Patents

VERFAHREN UND ZUSAMMENSETZUNGEN ZUR VERLûNGERUNG DER LEBENSDAUER UND ERH HUNG DER STRESSRESISTENZ VON ZELLEN UND ORGANISMEN

Info

Publication number
EP1551964A4
EP1551964A4 EP03788377A EP03788377A EP1551964A4 EP 1551964 A4 EP1551964 A4 EP 1551964A4 EP 03788377 A EP03788377 A EP 03788377A EP 03788377 A EP03788377 A EP 03788377A EP 1551964 A4 EP1551964 A4 EP 1551964A4
Authority
EP
European Patent Office
Prior art keywords
organisms
compositions
cells
increasing
extending
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03788377A
Other languages
English (en)
French (fr)
Other versions
EP1551964A2 (de
Inventor
David A Sinclair
Kevin J Bitterman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Priority to EP11179088A priority Critical patent/EP2431480A3/de
Publication of EP1551964A2 publication Critical patent/EP1551964A2/de
Publication of EP1551964A4 publication Critical patent/EP1551964A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
EP03788377A 2002-08-09 2003-08-08 VERFAHREN UND ZUSAMMENSETZUNGEN ZUR VERLûNGERUNG DER LEBENSDAUER UND ERH HUNG DER STRESSRESISTENZ VON ZELLEN UND ORGANISMEN Withdrawn EP1551964A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11179088A EP2431480A3 (de) 2002-08-09 2003-08-08 Verfahren und Zusammensetzungen zur Erhöhung der Stressresistenz von Zellen und Organismen

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40225402P 2002-08-09 2002-08-09
US402254P 2002-08-09
US42861402P 2002-11-22 2002-11-22
US428614P 2002-11-22
PCT/US2003/025016 WO2004016726A2 (en) 2002-08-09 2003-08-08 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms

Publications (2)

Publication Number Publication Date
EP1551964A2 EP1551964A2 (de) 2005-07-13
EP1551964A4 true EP1551964A4 (de) 2010-07-28

Family

ID=31720582

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11179088A Withdrawn EP2431480A3 (de) 2002-08-09 2003-08-08 Verfahren und Zusammensetzungen zur Erhöhung der Stressresistenz von Zellen und Organismen
EP03788377A Withdrawn EP1551964A4 (de) 2002-08-09 2003-08-08 VERFAHREN UND ZUSAMMENSETZUNGEN ZUR VERLûNGERUNG DER LEBENSDAUER UND ERH HUNG DER STRESSRESISTENZ VON ZELLEN UND ORGANISMEN

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP11179088A Withdrawn EP2431480A3 (de) 2002-08-09 2003-08-08 Verfahren und Zusammensetzungen zur Erhöhung der Stressresistenz von Zellen und Organismen

Country Status (5)

Country Link
EP (2) EP2431480A3 (de)
JP (3) JP2005535342A (de)
AU (2) AU2003264037B2 (de)
CA (2) CA2421269A1 (de)
WO (1) WO2004016726A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
EP1727546A4 (de) * 2003-10-31 2008-07-09 Robarts Res Inst Verfahren und formulierungen zum schutz von zellen und zur behandlung von krankheiten und leiden durch optimierung der intrazellulären nad-konzentration
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
JP2007527418A (ja) 2003-12-29 2007-09-27 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 肥満及びインシュリン耐性障害を治療又は防止するための組成物
AU2005257883A1 (en) * 2004-06-04 2006-01-05 Washington University Methods and compositions for treating neuropathies
US7851675B2 (en) 2004-09-24 2010-12-14 Bayer Bioscience N.V. Stress resistant plants
EP1844157A4 (de) * 2005-01-25 2009-11-25 Univ Johns Hopkins Strategien für das design von auf die sir2-familie von enzymen abzielenden wirkstoffen
CA2610854A1 (en) 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
AU2006257420B2 (en) * 2005-06-15 2011-05-26 Bayer Cropscience Nv. Methods for increasing the resistance of plants to hypoxic conditions
US8158856B2 (en) 2006-03-21 2012-04-17 Bayer Cropscience Nv Stress resistant plants
CN101557709B (zh) 2006-12-11 2016-01-27 国立研究开发法人科学技术振兴机构 植物生长调整剂及其利用
US8268748B2 (en) * 2007-11-13 2012-09-18 Japan Science And Technology Agency Composition for production of plant body having improved sugar content, and use thereof
JP5570731B2 (ja) * 2008-02-28 2014-08-13 旭化成ファーマ株式会社 ピロリン酸の測定方法
EP2259782A4 (de) 2008-03-03 2013-01-23 Nad Life Pty Ltd Pharmazeutische formulierungen von resveratrol und verfahren zur ihrer anwendung bei der behandlung von zellerkrankungen
JP2011115098A (ja) * 2009-12-04 2011-06-16 Nippon Menaade Keshohin Kk 加齢による皮膚明度の低下を予測する皮膚評価方法
JP5967780B2 (ja) 2011-12-12 2016-08-10 岡山県 植物のアミノ酸含量を高めるための化合物およびその利用
WO2014059034A2 (en) 2012-10-09 2014-04-17 President And Fellows Of Harvard College Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
US20160287621A1 (en) * 2013-11-06 2016-10-06 President And Fellows Of Harvard College Biological production of nad precursors and analogs
RU2016149764A (ru) 2014-06-02 2018-07-17 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед Получение и применение кристаллического бета-d-никотинамида рибозида
BR112016028672A2 (pt) 2014-06-06 2017-08-22 Glaxosmithkline Ip No 2 Ltd análogos de ribosídeo de nicotinamida e composições farmacêuticas e usos do mesmo
WO2020097116A1 (en) * 2018-11-05 2020-05-14 Rejuvenation Therapeutics Compositions and methods for culturing yeast cells
CN111394268B (zh) * 2019-12-20 2021-06-18 合肥康诺生物制药有限公司 基因工程菌及其构建方法、应用，生产nad+的方法
CN112451673A (zh) * 2020-12-10 2021-03-09 汤臣倍健股份有限公司 线粒体功能干预材料在制备改善线粒体功能的保健品或药品中的应用及其筛选方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987000201A1 (en) 1985-07-05 1987-01-15 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
WO1989002468A1 (en) 1987-09-11 1989-03-23 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
EP0391960B1 (de) 1987-12-11 1994-08-17 Whitehead Institute For Biomedical Research Genetische modifizierung von endothelialen zellen
EP0400047B1 (de) 1988-02-05 1997-04-23 Whitehead Institute For Biomedical Research Modifizierte hepatozyten und deren anwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2095256A1 (en) 1990-10-31 1992-05-01 Brad Guild Retroviral vectors useful for gene therapy
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
JPH08504091A (ja) 1992-09-22 1996-05-07 メディカル・リサーチ・カウンシル 外部表面に非ウィルス性ポリペプチドを提示する組換えウィルス
AU688292B2 (en) 1992-11-09 1998-03-12 United States Government as represented by the Department of Health and Human Services, The Targetable vector particles
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
ATE399873T1 (de) 1993-07-13 2008-07-15 Centelion Defekte adenovirus-vektoren und deren verwendung in der gentherapie
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
ATE336587T1 (de) 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
PT787200E (pt) 1994-10-28 2005-08-31 Univ Pennsylvania Adenovirus melhorado e metodos para a sua utilizacao
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
JPH10510987A (ja) 1994-12-12 1998-10-27 ジェネティック セラピー，インコーポレイテッド 改良アデノウイルスベクターおよび生産者細胞
ATE352634T1 (de) 1995-02-24 2007-02-15 Univ Pennsylvania Benutzung von immunmodulatoren zur herstellung von medikamenten zur inhibierung einer immunantwort gegen gleichzeitig verabreichte rekombinante viren
US5688676A (en) 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
WO1997008298A1 (en) 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
GB9816781D0 (en) 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
US20040081618A1 (en) * 2000-10-03 2004-04-29 Tatsuji Enoki Method of screening physiologically active substance
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US9515947B1 (en) 2013-03-15 2016-12-06 EMC IP Holding Company LLC Method and system for providing a virtual network-aware storage array
KR20160071054A (ko) 2014-12-11 2016-06-21 에스케이하이닉스 주식회사 반도체 메모리 장치 및 그의 동작 방법
US9609948B2 (en) 2015-04-28 2017-04-04 Qianglong Furniture Co., Ltd. Rotating armrest apparatus

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CROWLEY C L ET AL: "The NAD+ precursors, nicotinic acid and nicotinamide protect cells against apoptosis induced by a multiple stress inducer, deoxycholate", CELL DEATH AND DIFFERENTIATION, vol. 7, no. 3, March 2000 (2000-03-01), Great Britain, pages 314 - 326, XP000953224, ISSN: 1350-9047, DOI: 10.1038/sj.cdd.4400658 *
DRAGOVIC J ET AL: "Phase I/II study of pentoxifylline and nicotinamide in combination with radiation therapy in locally advanced cancers", INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol. 24, no. SUPPL. 1, 1992, & 34TH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY, SAN DIEGO, CALIF, pages 272 - 273, XP026844395, ISSN: 0360-3016 *
GOTOH HIROKO: "Inhibitory effects of nicotinamide on the growth of transplanted murine breast cancer and urethane-initiated lung tumorigenesis in mice", VITAMINS, vol. 67, no. 9, 1993, KYOTO, pages 469 - 479, XP008036628, ISSN: 0006-386X *
KNIP M ET AL: "Safety of high-dose nicotinamide: A review", DIABETOLOGIA, vol. 43, no. 11, November 2000 (2000-11-01), Germany, pages 1337 - 1345, XP009134696, ISSN: 0012-186X, DOI: 10.1007/s001250051536 *
SESTILI P ET AL.: "Structural requirements for inhibitors of poly(ADP-ribose) polymerase.", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, LNKD- PUBMED:2123880, vol. 116, no. 6, 1990, GERMANY, pages 615 - 622, XP009134778, ISSN: 0171-5216 *

Also Published As

Publication number Publication date
CA2421269A1 (en) 2004-02-09
WO2004016726A2 (en) 2004-02-26
WO2004016726A3 (en) 2005-05-19
JP2015198665A (ja) 2015-11-12
JP6602561B2 (ja) 2019-11-06
WO2004016726A9 (en) 2005-08-04
JP2011015682A (ja) 2011-01-27
AU2003264037A1 (en) 2004-03-03
AU2010219395B2 (en) 2011-07-14
AU2003264037B2 (en) 2010-06-17
CA2495185A1 (en) 2004-02-26
EP1551964A2 (de) 2005-07-13
JP2005535342A (ja) 2005-11-24
EP2431480A3 (de) 2012-09-05
EP2431480A2 (de) 2012-03-21
AU2010219395A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
EP1551964A4 (de) VERFAHREN UND ZUSAMMENSETZUNGEN ZUR VERLûNGERUNG DER LEBENSDAUER UND ERH HUNG DER STRESSRESISTENZ VON ZELLEN UND ORGANISMEN
EP1689854A4 (de) Plazentastammzellen und verwendungen davon
AU2003220205A8 (en) Ethanol-diesel fuel composition and methods thereof
EP1682150A4 (de) Zusammensetzungen und verfahren zur induktion von zellentdifferenzierung
EP1519431A4 (de) Elektrode und elektrochemische zelle diese enthaltend
AU2003216058A8 (en) Mammalian neural stem cells, compositions and uses thereof
GB2427616B (en) Stem cells
GB0410159D0 (en) Battery charger and assembly
DE60330220D1 (de) Feststoffelektrolyt und Feststoffbatterie enthaltend diesen Elektrolyten
AU2003279229A8 (en) Fuel cell assembly and method of making the same
EP1487033A4 (de) Batterie und verfahren zur herstellung der batterie
IL166370A0 (en) Embryonic stem cell markers and uses thereof
GB0212825D0 (en) Methods compositions and kits for cell separation
AU2003294246A8 (en) Circulating stem cells and uses related thereto
AU2003290432A8 (en) T cell activating gene
GB0202059D0 (en) Chemical compositions and methods
HK1126815A1 (en) Entrapped stem cells and uses thereof
EP1558086A4 (de) Zelltargeting-verfahren und zusammensetzungen
TW572368U (en) Stackable battery and stackable battery assembly
EP1623560A4 (de) Drehmomentzelle
HK1097875A1 (en) Adenovirus-transfected primary cells and methods of pathway mapping
AU2003221022A1 (en) Herbicidal composition and method of weeding with the same
GB0300558D0 (en) Method for the testing of multiple materials for electrochemical uses
EP1636341A4 (de) Stammzellen für klinische und kommerzielle anwendungen
AU2003297297A8 (en) Elf3 gene compositions and methods

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050308

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20100628

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101ALI20100622BHEP

Ipc: C07K 14/47 20060101ALI20100622BHEP

Ipc: A61K 38/45 20060101ALI20100622BHEP

Ipc: A01N 25/00 20060101ALI20100622BHEP

Ipc: C07H 21/04 20060101ALI20100622BHEP

Ipc: C12Q 1/58 20060101ALI20100622BHEP

Ipc: C12Q 1/00 20060101ALI20100622BHEP

Ipc: C12N 1/20 20060101ALI20100622BHEP

Ipc: C12N 9/12 20060101ALI20100622BHEP

Ipc: G01N 33/573 20060101AFI20100622BHEP

17Q First examination report despatched

Effective date: 20110217

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110830